ReviewInflammopharmacology2025
Neuroprotective potential of indian herbs in ischaemic stroke: a comprehensive review of pharmacological insights, therapeutic gaps, and future directions.
Review in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stroke is the second most common cause of mortality worldwide and a major contributor to acquired disability. Current treatment options, such as recombinant tissue plasminogen activator (r-tPA), are restricted by a narrow therapeutic window and an increased risk of cerebral haemorrhage. Herbal medicines demonstrate considerable potential in the management of ischaemic stroke by modulating key pathological processes, including blood-brain barrier disruption, neuroinflammation, apoptosis, oxidative stress, glutamate excitotoxicity, and mitochondrial dysfunction. This review identified the gaps from preclinical and clinical studies on neuroprotective plants and their phytoconstituents from India, with particular emphasis on the cellular, molecular, and genetic mechanisms implicated in stroke pathology. Furthermore, it evaluates the strengths and limitations of plant extracts, bioactive compounds, and formulations employed in ischaemic stroke therapy. Identified research gaps include insufficient long-term safety data, limited pharmacokinetic insights, and inadequate delivery systems. These highlight the need for advanced investigations to optimise formulation strategies, dosing regimens, and clinical translation. Collectively, these insights provide a basis for the development of effective, natural therapeutic approaches for ischaemic stroke.
Indexed as
Identifiers
41243069What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.